Key facts
- It has raised $2.6M; the latest was Seed Round ($1.4M) in Dec 2025.
- Notable investors include SOSV, Venture Kick, IndieBio, Innosuisse, EFI Lake Geneva Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for FluoSphera
- ·The full record, as it builds
Funding rounds
No funding rounds for FluoSphera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FluoSphera
Developer of a drug discovery platform designed to help companies and organizations protect people from harmful compounds. The company's platform helps discover efficient drugs with fewer adverse side effects and reduces animal experimentation, enabling companies to address the complexity of human physiological responses and protect populations efficiently from hazardous chemicals.
- Sector
- Healthcare
- HQ
- Geneva, Switzerland
- Founded
- 2021
- Employees
- 5
- Website
- fluosphera.com/
- Ownership
- Privately Held (backing)
FluoSphera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FluoSphera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FluoSphera in its N-PORT filings yet. We sweep new filings monthly.